Specialty Pharmacy

Top news of the day from across the health care landscape.

Investigators aim to determine whether Zika virus interferes with antiretroviral drugs that prevent mother-to-child transmission of HIV.

Biosimilars have the potential to achieve billions in savings, but significant challenges remain.

Report finds socioeconomic factors that increase vulnerability to HIV.

Tremfya is the first and only approved biologic that selectively blocks the interleukin-23 protein.

A look at last week's top stories in the world of pharmacy.

Tremfya found to achieve significantly clearer skin in moderate to severe plaque psoriasis.

Voluntary medical male circumcision may help to reduce the spread of HIV.

Top news of the day from across the health care landscape.

Emicizumab is administered subcutaneously only once per week compared with clotting factors administered intravenously 3 times per week.

Selective oral immunomodulator plus tenofovir alafenamide (Vemlidy) seeks functional cure in chronic HBV.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how recently proposed transparency legislation may affect specialty pharmacies.

CTL019 is a chimeric antigen receptor T cell therapy.

Top news of the day from across the health care landscape.

Increasingly, individuals with HIV also have comorbid conditions, such as cardiovascular disease, hypertension, and diabetes.

The once-daily drug contains bictegravir and emtricitabine/tenofovir to treat adults with HIV-1.

Study finds the current reimbursement model for biosimilars needs to be adjusted to improve uptake.

No data were presented for treatment-naïve and pretreated adolescents with hepatitis B virus.

Abemaciclib is a CDK4/6 inhibitor being explored in advanced breast cancer.

Investigators believe oral duvelisib may represent an important new treatment option for lymphoma patients.

Competition in HIV drug development affecting stock market.

Clinical trials to begin for an investigational approach to treating glioma.

Inhibiting particle release and infectivity could lead to a cure for HIV-1.

Top news of the day from across the health care landscape.

Merck will present late-breaker abstracts at upcoming IAS 2017 conference.

Cancer diagnoses delayed by an average of 9 days in patients with preexisting conditions.

Over-the-counter therapy could improve overall wellbeing in patients with multiple sclerosis.

The Biologics License Application for ibalizumab is under review for the treatment of multidrug resistant HIV-1.